PMID- 2674359
OWN - NLM
STAT- MEDLINE
DCOM- 19891019
LR  - 20220318
IS  - 0390-5616 (Print)
IS  - 0390-5616 (Linking)
VI  - 33
IP  - 1
DP  - 1989 Jan-Mar
TI  - Modulation of glycolysis in neuroepithelial tumors.
PG  - 55-64
AB  - Among the features of the reprogrammed neoplastic phenotype there is the 
      metabolic property to display an increased glycolytic capacity and the ability to 
      convert glucose to lactic acid in the presence of oxygen. Human gliomas in vivo 
      and in vitro are capable to metabolize glucose in a way strictly related to the 
      pathological degree of malignancy. The drug Lonidamine 
      [1-(2,4-dichlorobenzyl)-1H-indazol-3 carboxylic acid)] (LND) is able to 
      selectively block hexokinase (HK) activity and, consequently, lactate production 
      only in highly glycolytic (highly malignant) gliomas, stimulating, on the 
      contrary, that of low grade gliomas; this basically depends on the different HK 
      patterns between low and high grade gliomas. LND is under clinical trial in order 
      to evaluate its effectiveness in glioma therapy.
FAU - Floridi, A
AU  - Floridi A
AD  - Regina Elena Institute for Cancer Research, Rome, Italy.
FAU - Paggi, M G
AU  - Paggi MG
FAU - Fanciulli, M
AU  - Fanciulli M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Italy
TA  - J Neurosurg Sci
JT  - Journal of neurosurgical sciences
JID - 0432557
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indazoles)
RN  - 0 (Pyrazoles)
RN  - EC 2.7.1.1 (Hexokinase)
RN  - U78804BIDR (lonidamine)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Brain Neoplasms/*metabolism
MH  - Glioma/*metabolism
MH  - Glycolysis/*drug effects
MH  - Hexokinase/metabolism
MH  - Humans
MH  - Indazoles/*pharmacology
MH  - Pyrazoles/*pharmacology
RF  - 65
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - J Neurosurg Sci. 1989 Jan-Mar;33(1):55-64.